Carcinoma, Lobular clinical trials
The registry lists 69 studies for Carcinoma, Lobular across more than 10 countries. 18 are recruiting or about to start. 25 of them are mainly about Carcinoma, Lobular (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-10.
Get an email when these change. Save the Carcinoma, Lobular studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
Memorial Sloan Kettering Cancer Center (4) · City of Hope Medical Center (3) · Dana-Farber Cancer Institute (3) · Intarcia Therapeutics (3) · University of California, Davis (2) · Alliance for Clinical Trials in Oncology (2) · University of California, San Francisco (2) · M.D. Anderson Cancer Center (2)
What is being tested here
Drugs under test in Carcinoma, Lobular studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
| Drug | Open | Phase 3 | All |
|---|---|---|---|
| Gallium-68 | 2 | 0 | 2 |
| Anastrozole | 1 | 1 | 2 |
| Neoantigen Peptide Vaccine | 1 | 0 | 1 |
| Fluoroestradiol f-18 | 1 | 0 | 1 |
| Exemestane | 1 | 0 | 1 |
| Letrozole | 0 | 3 | 5 |
| Trastuzumab | 0 | 0 | 3 |
| Carboplatin | 0 | 0 | 3 |
| Atamestane | 0 | 3 | 3 |
| Toremifene | 0 | 3 | 3 |
Drug classes tested here Aromatase inhibitors 1 open · Antimitotic agents 3
Coming up
10studies finish main data collection within a year1 of them phase 3
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
All 10, phase 3 first
- Apr 2027Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery · Phase 3 · Alliance for Clinical Trials in Oncology
- Nov 2026Initial Staging of Lobular Breast Carcinoma: Head to Head Comparison of 68Ga-FAPI-46 and 18F-FDG PET/CT · Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer
- Dec 2026Biomarkers to Detect Endocrine Therapy Resistance · University of Wisconsin, Madison
- May 2027Negative/Low Hormone Receptor And/or HER2 POsitive Lobular Invasive Breast Carcinoma - A Real-World International Cohort Study · Istituto Oncologico Veneto IRCCS
- May 2027[68]GA-FAPI-46 PET/CT for the Diagnosis of Metastatic Lesions in Patients With Lobular Breast Cancer (ICL). · Hospices Civils de Lyon
- Jun 2027[68Ga]Ga DOTA-5G as a Diagnostic Imaging Agent for Metastatic/Advanced Invasive Lobular Breast Cancer (LBC) · University of California, Davis
- Jul 2027Radiation Therapy in Treating Women With Early Stage Breast Cancer · Rutgers, The State University of New Jersey
- Jul 2027A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue · Memorial Sloan Kettering Cancer Center
- Aug 2027A Study Comparing Cancer Imaging Approaches in People With Lobular Breast Cancer · Memorial Sloan Kettering Cancer Center
- Sep 2027A Trial Evaluating the Efficacy of Ivonescimab in Metastatic Endocrine Refractory HR-positive HER2-negative or Triple Negative Invasive Lobular Carcinoma · M.D. Anderson Cancer Center
Who these studies take
Of the 15 Carcinoma, Lobular studies recruiting now, 12 (80%) set no upper age limit and 0 (0%) stop at 75 or younger. 2 (13%) take children under 18. 4 (27%) are for women only and 0 (0%) for men only; 1 (7%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 1 (7%) | 1 (7%) |
| 18 | 14 (93%) | 11 (73%) |
| 30 | 14 (93%) | 11 (73%) |
| 40 | 14 (93%) | 11 (73%) |
| 50 | 15 (100%) | 11 (73%) |
| 65 | 15 (100%) | 11 (73%) |
| 75 | 15 (100%) | 11 (73%) |
| 85 | 13 (87%) | 9 (60%) |
Across all 69 studies, recruiting or not: 4% stop at 75 or younger and 4% at 65; 7% take children; 54% are for women only and 0% for men only; 4% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
What changed recently
From the registry's own updates since Oct 13, 2026.
Started recruiting1
- FES PET/MRI for Occult Disease in Lobular Breast CancerNov 10, 2026NCT07910474
Newly registered1
- FES PET/MRI for Occult Disease in Lobular Breast CancerNov 2, 2026NCT07910474
Studies
Recruiting first, then most recently updated. Showing 50 of 69. Browse all 69 → or search them.
- FES PET/MRI for Occult Disease in Lobular Breast CancerRecruitingNCT07910474Phase 41 country
- Improving Survival for Metastatic Lobular Breast Cancer (PLUMB Registry)RecruitingNCT059645041 country
- Negative/Low Hormone Receptor And/or HER2 POsitive Lobular Invasive Breast Carcinoma - A Real-World International Cohort StudyRecruitingNCT076131511 country
- [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology IndicationsRecruitingNCT07432633Phase 1/21 country
- [68Ga]BED003 PET Imaging of Fibroblast Activation Protein in Selected Oncology IndicationsRecruitingNCT07702292Phase 22 countries
- [68Ga]Ga DOTA-5G as a Diagnostic Imaging Agent for Metastatic/Advanced Invasive Lobular Breast Cancer (LBC)RecruitingNCT07020806Phase 11 country
- A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft TissueRecruitingNCT05837767Not applicable1 country
- Biomarkers to Detect Endocrine Therapy ResistanceRecruitingNCT06067503Phase 21 country
- Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid TumorsRecruitingNCT05269381Phase 1/21 country
- Neoadjuvant Neratinib in Stage I-III HER2-Mutated Lobular Breast CancersRecruitingNCT05919108Phase 21 country
- InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for CancerRecruitingNCT054637961 country
- A Trial Evaluating the Efficacy of Ivonescimab in Metastatic Endocrine Refractory HR-positive HER2-negative or Triple Negative Invasive Lobular CarcinomaRecruitingNCT07229417Phase 21 country
- 18F FES-PET/MRI for Tailoring Treatment of Luminal A and Lobular Breast CancerRecruitingNCT05982496Phase 21 country
- Disease Extent in Stage IV Lobular Carcinoma: the Aid of Imaging and Liquid Biopsy AnalysesNot yet recruitingNCT07635654Not applicable
- A Study of the Impact of Endocrine Therapy on Surgical Outcomes in People With Lobular Breast CancerRecruitingNCT07483307Phase 21 country
- HISMAR: Intraoperative Margin Assessment Using the Histolog® Scanner to Reduce Reoperation in Breast-Conserving SurgeryNot yet recruitingNCT07527468Not applicable1 country
- Longitudinal Tumor Burden Quantification Using Circulating Tumor DNA in Metastatic Lobular Breast CancerRecruitingNCT066664391 country
- [68]GA-FAPI-46 PET/CT for the Diagnosis of Metastatic Lesions in Patients With Lobular Breast Cancer (ICL).Not yet recruitingNCT07313033Not applicable1 country
- Studying Blood and Tumor Tissue Samples in Women With Invasive Breast Cancer, Ductal or Lobular Carcinoma in Situ, or Benign Breast DiseaseCompletedNCT008985081 country
- AI-based Prognostic Factors Identification in Early-stage Invasive Lobular Breast CarcinomaCompletedNCT078420551 country
- Combination Chemotherapy With or Without Trastuzumab in Treating Patients With Stage II or Stage III Breast CancerActive, not recruitingNCT00295893Phase 21 country
- A Study Comparing Cancer Imaging Approaches in People With Lobular Breast CancerActive, not recruitingNCT065571481 country
- Initial Staging of Lobular Breast Carcinoma: Head to Head Comparison of 68Ga-FAPI-46 and 18F-FDG PET/CTActive, not recruitingNCT05931302Not applicable1 country
- Palbociclib and Endocrine Therapy for LObular Breast Cancer Preoperative Study (PELOPS)Active, not recruitingNCT02764541Phase 21 country
- Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing SurgeryActive, not recruitingNCT01953588Phase 32 countries
- Demographics, Characteristics and Outcomes of Male Breast Cancer Patients at Methodist Health SystemCompletedNCT061336471 country
- Carboplatin and Nab-Paclitaxel With or Without Vorinostat in Treating Women With Newly Diagnosed Operable Breast CancerActive, not recruitingNCT00616967Phase 21 country
- Hypofractionated Radiation Therapy After Mastectomy in Preventing Recurrence in Patients With Stage IIa-IIIa Breast CancerActive, not recruitingNCT03414970Phase 32 countries
- Phase II Study of REPotrectinib With or Without Fulvestrant in Patients With Hormone Receptor-positive Human Epidermal Growth Factor 2-negative Metastatic Invasive LObular Carcinoma Who Received a Prior Endocrine Therapy in Combination With Cyclin-dependent Kinase 4 and 6 Inhibitor (REPLOT Trial)TerminatedNCT06408168Phase 21 country
- LobularCard Trial: Searching for Novel Germline Mutations in Lobular Breast Cancer PatientsActive, not recruitingNCT054109511 country
- CDH1 Germline Mutations in Lobular Breast CancerCompletedNCT042068911 country
- Crizotinib in Lobular Breast, Diffuse Gastric and Triple Negative Lobular Breast Cancer or CDH1-mutated Solid TumoursCompletedNCT03620643Phase 21 country
- Caloric Restriction in Treating Patients With Stage 0-I Breast Cancer Undergoing Surgery and Radiation TherapyCompletedNCT01819233Not applicable1 country
- [18F]Fluoroestradiol-PET/CT Imaging of Invasive Lobular CarcinomaTerminatedNCT04252859Phase 21 country
- Fluciclovine and PSMA PET/CT for the Classification and Improved Staging of Invasive Lobular Breast CancerCompletedNCT04750473Phase 11 country
- Neoadjuvant Study of Targeting ROS1 in Combination With Endocrine Therapy in Invasive Lobular Carcinoma of the Breast (ROSALINE)Active, not recruitingNCT04551495Phase 22 countries
- Diagnostic Performance of [18F]FES PET/CT for Axillary LN Metastasis in Invasive Lobular CarcinomaCompletedNCT05960201Phase 21 country
- Hypofractionated Image Guided Radiation Therapy in Treating Patients With Stage IV Breast CancerCompletedNCT017064321 country
- Radiation Therapy in Treating Women With Early Stage Breast CancerActive, not recruitingNCT00909909Phase 21 country
- Accelerated Radiation Therapy After Surgery in Treating Patients With Breast CancerCompletedNCT01417286Phase 21 country
- Genetic Testing or Clinical Assessment in Determining the Need for Chemotherapy in Women With Breast Cancer That Involves No More Than 3 Lymph NodesCompletedNCT00433589Phase 31 country
- Radiation Therapy in Treating Women With Locally Recurrent Breast Cancer Previously Treated With Repeat Breast-Preserving SurgeryCompletedNCT01082211Phase 22 countries
- Single Fraction Intraoperative RadiotherapyCompletedNCT01688388Not applicable1 country
- Naltrexone RCT for Treatment-Emergent Fatigue in Patients Receiving Radiation Therapy for Breast CancerTerminatedNCT02137252Phase 21 country
- Living Well After Breast SurgeryCompletedNCT03834532Not applicable1 country
- Molecular Genetic Basis of Invasive Breast Cancer Risk Associated With Lobular Carcinoma in SituCompletedNCT005817501 country
- Intraoperative Imaging of Breast Cancer With Indocyanine GreenCompletedNCT01796041Early Phase 11 country
- Partial Breast Radiation Therapy in Treating Women Undergoing Breast Conservation Therapy for Early-Stage Breast CancerCompletedNCT00599989Not applicable1 country
- Broccoli Sprout Extract in Treating Patients With Breast CancerCompletedNCT01753908Early Phase 11 country
- Magnetic Resonance Imaging in Women Recently Diagnosed With Unilateral Breast CancerCompletedNCT00058058Not applicable3 countries